Loading...
Thumbnail Image
Publication

NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice.

Heneka, Michael T
Kummer, Markus P
Stutz, Andrea
Delekate, Andrea
Schwartz, Stephanie
Vieira-Saecker, Ana
Griep, Angelika
Axt, Daisy
Remus, Anita
Tzeng, Te-Chen
... show 5 more
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2013-01-31
Submitted date
Other Titles
Abstract
Alzheimer's disease is the world's most common dementing illness. Deposition of amyloid-β peptide drives cerebral neuroinflammation by activating microglia. Indeed, amyloid-β activation of the NLRP3 inflammasome in microglia is fundamental for interleukin-1β maturation and subsequent inflammatory events. However, it remains unknown whether NLRP3 activation contributes to Alzheimer's disease in vivo. Here we demonstrate strongly enhanced active caspase-1 expression in human mild cognitive impairment and brains with Alzheimer's disease, suggesting a role for the inflammasome in this neurodegenerative disease. Nlrp3(-/-) or Casp1(-/-) mice carrying mutations associated with familial Alzheimer's disease were largely protected from loss of spatial memory and other sequelae associated with Alzheimer's disease, and demonstrated reduced brain caspase-1 and interleukin-1β activation as well as enhanced amyloid-β clearance. Furthermore, NLRP3 inflammasome deficiency skewed microglial cells to an M2 phenotype and resulted in the decreased deposition of amyloid-β in the APP/PS1 model of Alzheimer's disease. These results show an important role for the NLRP3/caspase-1 axis in the pathogenesis of Alzheimer's disease, and suggest that NLRP3 inflammasome inhibition represents a new therapeutic intervention for the disease.
Citation
NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. 2013, 493 (7434):674-8 Nature
Affiliation
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
1476-4687
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
License
Archived with thanks to Nature